Alnylam To Host Fourth Annual "RNAi Roundtable" Webcast Series

Published: Jul 27, 2017

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that it plans to host its 4th annual series of “RNAi Roundtable” webcasts this summer and early fall. The 2017 series will offer a range of presentations from Alnylam scientists, clinical collaborators, and patients or patient advocates, who will review recent progress in many of the Company’s late-stage pipeline programs. In addition, one roundtable will report the findings from the investigation into the ENDEAVOUR Phase 3 trial with revusiran. Each event will be webcast live on the Investors page of the Company’s website,, and a replay of the roundtables will be posted on the Alnylam website approximately three hours after each event.

The 2017 RNAi Roundtable schedule will be as follows:

  • Patisiran, in development for the treatment of hereditary ATTR amyloidosis
    Thursday, August 3, 10:30 am ET
  • Revusiran investigation results
    Wednesday, August 9, 12:30 pm ET
  • Platform advances in RNAi therapeutics
    Wednesday, August 23, 3:30 pm ET
  • Givosiran, in development for the treatment of acute hepatic porphyrias
    Thursday, September 7, 10:30 am ET
  • Fitusiran, in development for the treatment of hemophilia and rare bleeding disorders
    Tuesday, September 12, 10:30 am ET

About RNAi

RNAi (RNA interference) is a revolution in biology, representing a breakthrough in understanding how genes are turned on and off in cells, and a completely new approach to drug discovery and development. Its discovery has been heralded as "a major scientific breakthrough that happens once every decade or so," and represents one of the most promising and rapidly advancing frontiers in biology and drug discovery today which was awarded the 2006 Nobel Prize for Physiology or Medicine. RNAi is a natural process of gene silencing that occurs in organisms ranging from plants to mammals. By harnessing the natural biological process of RNAi occurring in our cells, the creation of a major new class of medicines, known as RNAi therapeutics, is on the horizon. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam's RNAi therapeutic platform, target the cause of diseases by potently silencing specific mRNAs, thereby preventing disease-causing proteins from being made. RNAi therapeutics have the potential to treat disease and help patients in a fundamentally new way.

About Alnylam Pharmaceuticals

Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of patients who have limited or inadequate treatment options. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust discovery platform and deep pipeline of investigational medicines, including three product candidates that are in late-stage development or will be in 2017. Looking forward, Alnylam will continue to execute on its "Alnylam 2020" strategy of building a multi-product, commercial-stage biopharmaceutical company with a sustainable pipeline of RNAi-based medicines. For more information about our people, science and pipeline, please visit and engage with us on Twitter at @Alnylam.

Alnylam Pharmaceuticals, Inc.
Investors and Media:
Christine Regan Lindenboom, 617-682-4340
Josh Brodsky, 617-551-8276

Back to news